The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma

International Journal of Molecular Sciences

Volumn 16, Issue 2, 2015, Pages 4190-4208

  Lieber, Justus ^a   Armeanu Ebinger, Sorin ^a   Fuchs, Jörg ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

ABT 737; BH3 mimetic drugs; Metastases; Modulation of apoptosis; Multi drug resistance; Obatoclax; Pediatric hepatoblastoma

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALPHA FETOPROTEIN; CARBOPLATIN; CASPASE 3; CASPASE 7; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; NAVITOCLAX; OBATOCLAX; PACLITAXEL; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN CDC42; PROTEIN MCL 1; SCATTER FACTOR; SORAFENIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VENETOCLAX; VINCRISTINE; ABT-737; BIPHENYL DERIVATIVE; MONOCLONAL ANTIBODY; NITROPHENOL; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS ASSAY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RISK; CELL CYCLE CHECKPOINT; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DISTANT METASTASIS FREE SURVIVAL; DOWN REGULATION; DRUG POTENTIATION; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEPATOBLASTOMA; HUMAN; IMMUNOMODULATION; MEMBRANE PERMEABILITY; METASTASIS INHIBITION; MIGRATION INHIBITION; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN MODIFICATION; REVIEW; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHILD; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BIPHENYL COMPOUNDS; CHILD; DRUG RESISTANCE, NEOPLASM; HEPATOBLASTOMA; HUMANS; LIVER NEOPLASMS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SULFONAMIDES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84923108178     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16024190     Document Type: Review

References (124)

1. Stiller, C.A.; Pritchard, J.; Steliarova-Foucher, E. Liver cancer in european children: Incidence and survival, 1978-1997. Report from the automated childhood cancer information system project. Eur. J. Cancer 2006, 42, 2115-2123.
2. Litten, J.B.; Tomlinson, G.E. Liver tumors in children. Oncologist 2008, 13, 812-820.
3. Pietsch, T.; Fonatsch, C.; Albrecht, S.; Maschek, H.; Wolf, H.K.; von Schweinitz, D. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab. Investig. 1996, 74, 809-818.
4. Doi, I. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma. Gann 1976, 67, 1-10.
5. Katzenstein, H.M.; London, W.B.; Douglass, E.C.; Reynolds, M.; Plaschkes, J.; Finegold, M.J.; Bowman, L.C. Treatment of unresectable and metastatic hepatoblastoma: A pediatric oncology group phase II study. J. Clin. Oncol. 2002, 20, 3438-3444.
6. Perilongo, G.; Shafford, E.; Maibach, R.; Aronson, D.; Brugieres, L.; Brock, P.; Childs, M.; Czauderna, P.; MacKinlay, G.; Otte, J.B.; et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the international society of paediatric oncology-SIOPEL 2. Eur. J. Cancer 2004, 40, 411-421.
7. Venkatramani, R.; Furman, W.L.; Fuchs, J.; Warmann, S.W.; Malogolowkin, M.H. Current and future management strategies for relapsed or progressive hepatoblastoma. Paediatr. Drugs 2012, 14, 221-232.
8. Von Schweinitz, D. Management of liver tumors in childhood. Semin. Pediatr. Surg. 2006, 15, 17-24.
9. Douglass, E.C.; Green, A.A.; Wrenn, E.; Champion, J.; Shipp, M.; Pratt, C.B. Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. Med. Pediatr. Oncol. 1985, 13, 187-190.
10. Perilongo, G.; Shafford, E.A. Liver tumours. Eur. J. Cancer 1999, 35, 953-958.
11. Aronson, D.C.; Schnater, J.M.; Staalman, C.R.; Weverling, G.J.; Plaschkes, J.; Perilongo, G.; Brown, J.; Phillips, A.; Otte, J.B.; Czauderna, P.; et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: Results from the international society of pediatric oncology liver tumor study group SIOPEL-1 study. J. Clin. Oncol. 2005, 23, 1245-1252.
12. Meyers, R.L.; Tiao, G.; de Ville de Goyet, J.; Superina, R.; Aronson, D.C. Hepatoblastoma state of the art: Pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr. Opin. Pediatr. 2014, 26, 29-36.
13. Brown, J.; Perilongo, G.; Shafford, E.; Keeling, J.; Pritchard, J.; Brock, P.; Dicks-Mireaux, C.; Phillips, A.; Vos, A.; Plaschkes, J. Pretreatment prognostic factors for children with hepatoblastoma-Results from the international society of paediatric oncology (SIOP) study SIOPEL 1. Eur. J. Cancer 2000, 36, 1418-1425.
14. Perilongo, G.; Maibach, R.; Shafford, E.; Brugieres, L.; Brock, P.; Morland, B.; de Camargo, B.; Zsiros, J.; Roebuck, D.; Zimmermann, A.; et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N. Engl. J. Med. 2009, 361, 1662-1670.
15. Zsiros, J.; Maibach, R.; Shafford, E.; Brugieres, L.; Brock, P.; Czauderna, P.; Roebuck, D.; Childs, M.; Zimmermann, A.; Laithier, V.; et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study. J. Clin. Oncol. 2009, 28, 2584-2590.
16. Fuchs, J.; Rydzynski, J.; von Schweinitz, D.; Bode, U.; Hecker, H.; Weinel, P.; Burger, D.; Harms, D.; Erttmann, R.; Oldhafer, K.; et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the german cooperative pediatric liver tumor study HB 94. Cancer 2002, 95, 172-182.
17. Haberle, B.; Bode, U.; von Schweinitz, D. Differentiated treatment protocols for high-and standard-risk hepatoblastoma-An interim report of the german liver tumor study HB99. Klin. Padiatr. 2003, 215, 159-165.
18. Malogolowkin, M.H.; Katzenstein, H.; Krailo, M.D.; Chen, Z.; Bowman, L.; Reynolds, M.; Finegold, M.; Greffe, B.; Rowland, J.; Newman, K.; et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J. Clin. Oncol. 2006, 24, 2879-2884.
19. Matsunaga, T.; Sasaki, F.; Ohira, M.; Hashizume, K.; Hayashi, A.; Hayashi, Y.; Mugishima, H.; Ohnuma, N.; Japanese Study Group for Pediatric Liver, T. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr. Surg. Int. 2003, 19, 142-146.
20. Ortega, J.A.; Douglass, E.C.; Feusner, J.H.; Reynolds, M.; Quinn, J.J.; Finegold, M.J.; Haas, J.E.; King, D.R.; Liu-Mares, W.; Sensel, M.G.; et al. Randomized comparison of cisplatin/vincristine/ fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the children's cancer group and the pediatric oncology group. J. Clin. Oncol. 2000, 18, 2665-2675.
21. Pritchard, J.; Brown, J.; Shafford, E.; Perilongo, G.; Brock, P.; Dicks-Mireaux, C.; Keeling, J.; Phillips, A.; Vos, A.; Plaschkes, J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: A successful approach-Results of the first prospective study of the international society of pediatric oncology. J. Clin. Oncol. 2000, 18, 3819-3828.
22. Zsiros, J.; Brugieres, L.; Brock, P.; Roebuck, D.; Maibach, R.; Zimmermann, A.; Childs, M.; Pariente, D.; Laithier, V.; Otte, J.B.; et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): A prospective, single-arm, feasibility study. Lancet Oncol. 2013, 14, 834-842.
23. Czauderna, P.; Otte, J.B.; Aronson, D.C.; Gauthier, F.; Mackinlay, G.; Roebuck, D.; Plaschkes, J.; Perilongo, G. Guidelines for surgical treatment of hepatoblastoma in the modern era-Recommendations from the childhood liver tumour strategy group of the international society of paediatric oncology (SIOPEL). Eur. J. Cancer 2005, 41, 1031-1036.
24. Otte, J.B.; de Ville de Goyet, J.; Reding, R. Liver transplantation for hepatoblastoma: Indications and contraindications in the modern era. Pediatr. Transplant. 2005, 9, 557-565.
25. Grotegut, S.; Kappler, R.; Tarimoradi, S.; Lehembre, F.; Christofori, G.; von Schweinitz, D. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by akt activation. Int. J. Oncol. 2010, 36, 1261-1267.
26. Warmann, S.W.; Armeanu, S.; Heigoldt, H.; Ruck, P.; Vonthein, R.; Heitmann, H.; Seitz, G.; Lemken, M.L.; Bitzer, M.; Fuchs, J.; et al. Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro. Pediatr. Blood Cancer 2009, 53, 145-151.
27. Eicher, C.; Dewerth, A.; Thomale, J.; Ellerkamp, V.; Hildenbrand, S.; Warmann, S.W.; Fuchs, J.; Armeanu-Ebinger, S. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. Br. J. Cancer 2013, 108, 334-341.
28. Hartmann, W.; Kuchler, J.; Koch, A.; Friedrichs, N.; Waha, A.; Endl, E.; Czerwitzki, J.; Metzger, D.; Steiner, S.; Wurst, P.; et al. Activation of phosphatidylinositol-3'-kinase/Akt signaling is essential in hepatoblastoma survival. Clin. Cancer Res. 2009, 15, 4538-4545.
29. McConkey, D.J.; Zhu, K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 2008, 11, 164-179.
30. Humeniuk, R.; Mishra, P.J.; Bertino, J.R.; Banerjee, D. Molecular targets for epigenetic therapy of cancer. Curr. Pharm. Biotechnol. 2009, 10, 161-165.
31. Tan, M.L.; Ooi, J.P.; Ismail, N.; Moad, A.I.; Muhammad, T.S. Programmed cell death pathways and current antitumor targets. Pharm. Res. 2009, 26, 1547-1560.
32. Warmann, S.W.; Frank, H.; Heitmann, H.; Ruck, P.; Herberts, T.; Seitz, G.; Fuchs, J. Bcl-2 gene silencing in pediatric epithelial liver tumors. J. Surg. Res. 2008, 144, 43-48.
33. Kobrinsky, N.L.; Sjolander, D.E.; Goldenberg, J.A.; Ortmeier, T.C. Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with beckwith-wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue. Pediatr. Blood Cancer 2005, 45, 222-225.
34. Inaba, H.; Handgretinger, R.; Furman, W.; Hale, G.; Leung, W. Allogeneic graft-versushepatoblastoma effect. Pediatr. Blood Cancer 2006, 46, 501-505.
35. Armeanu, S.; Bitzer, M.; Lauer, U.M.; Venturelli, S.; Pathil, A.; Krusch, M.; Kaiser, S.; Jobst, J.; Smirnow, I.; Wagner, A.; et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005, 65, 6321-6329.
36. Hoh, A.; Dewerth, A.; Vogt, F.; Wenz, J.; Baeuerle, P.A.; Warmann, S.W.; Fuchs, J.; Armeanu-Ebinger, S. The activity of gammadelta T cells against paediatric liver tumour cells and spheroids in cell culture. Liver Int. 2013, 33, 127-136.
37. Chang, J.F.; Chen, P.J.; Sze, D.Y.; Reid, T.; Bartlett, D.; Kirn, D.H.; Liu, T.C. Oncolytic virotherapy for advanced liver tumours. J. Cell. Mol. Med. 2009, 13, 1238-1247.
38. Warmann, S.W.; Armeanu, S.; Frank, H.; Buck, H.; Graepler, F.; Lemken, M.L.; Heitmann, H.; Seitz, G.; Lauer, U.M.; Bitzer, M.; et al. In vitro gene targeting in human hepatoblastoma. Pediatr. Surg. Int. 2006, 22, 16-23.
39. Von Schweinitz, D.; Hecker, H.; Schmidt-von-Arndt, G.; Harms, D. Prognostic factors and staging systems in childhood hepatoblastoma. Int. J. Cancer 1997, 74, 593-599.
40. Chu, G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 1994, 269, 787-790.
41. Oue, T.; Yoneda, A.; Uehara, S.; Yamanaka, H.; Fukuzawa, M. Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J. Pediatr. Surg. 2009, 44, 377-380.
42. Pommier, Y.; Leteurtre, F.; Fesen, M.R.; Fujimori, A.; Bertrand, R.; Solary, E.; Kohlhagen, G.; Kohn, K.W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investig. 1994, 12, 530-542.
43. Townsend, D.M.; Tew, K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22, 7369-7375.
44. Sigal, A.; Rotter, V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res. 2000, 60, 6788-6793.
45. Wong, R.S. Apoptosis in cancer: From pathogenesis to treatment. J. Exp. Clin. Cancer Res. 2011, 30, 87.
46. Chonghaile, T.N.; Letai, A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008, 27, S149-S157.
47. Chittenden, T.; Harrington, E.A.; O'Connor, R.; Flemington, C.; Lutz, R.J.; Evan, G.I.; Guild, B.C. Induction of apoptosis by the Bcl-2 homologue bak. Nature 1995, 374, 733-736.
48. Gibson, L.; Holmgreen, S.P.; Huang, D.C.; Bernard, O.; Copeland, N.G.; Jenkins, N.A.; Sutherland, G.R.; Baker, E.; Adams, J.M.; Cory, S. Bcl-w, a novel member of the Bcl-2 family, promotes cell survival. Oncogene 1996, 13, 665-675.
49. Nakano, K.; Vousden, K.H. Puma, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7, 683-694.
50. Wei, M.C.; Lindsten, T.; Mootha, V.K.; Weiler, S.; Gross, A.; Ashiya, M.; Thompson, C.B.; Korsmeyer, S.J. Tbid, a membrane-targeted death ligand, oligomerizes bak to release cytochrome c. Genes Dev. 2000, 14, 2060-2071.
51. Oda, E.; Ohki, R.; Murasawa, H.; Nemoto, J.; Shibue, T.; Yamashita, T.; Tokino, T.; Taniguchi, T.; Tanaka, N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288, 1053-1058.
52. Eskes, R.; Desagher, S.; Antonsson, B.; Martinou, J.C. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell. Biol. 2000, 20, 929-935.
53. Korsmeyer, S.J.; Wei, M.C.; Saito, M.; Weiler, S.; Oh, K.J.; Schlesinger, P.H. Pro-apoptotic cascade activates bid, which oligomerizes Bak or Bax into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7, 1166-1173.
54. Kim, H.; Rafiuddin-Shah, M.; Tu, H.C.; Jeffers, J.R.; Zambetti, G.P.; Hsieh, J.J.; Cheng, E.H. Hierarchical regulation of mitochondrion-dependent apoptosis by Bcl-2 subfamilies. Nat. Cell Biol. 2006, 8, 1348-1358.
55. Letai, A.; Bassik, M.C.; Walensky, L.D.; Sorcinelli, M.D.; Weiler, S.; Korsmeyer, S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2, 183-192.
56. Kang, M.H.; Reynolds, C.P. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15, 1126-1132.
57. Youle, R.J.; Strasser, A. The Bcl-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9, 47-59.
58. Bagnoli, M.; Canevari, S.; Mezzanzanica, D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: A key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int. J. Biochem. Cell Biol. 2009, 42, 210-213.
59. Safa, A.R.; Day, T.W.; Wu, C.H. Cellular FLICE-like inhibitory protein (c-FLIP): A novel target for cancer therapy. Curr. Cancer Drug Targets 2008, 8, 37-46.
60. Adesina, A.M.; Lopez-Terrada, D.; Wong, K.K.; Gunaratne, P.; Nguyen, Y.; Pulliam, J.; Margolin, J.; Finegold, M.J. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum. Pathol. 2009, 40, 843-853.
61. Lieber, J.; Kirchner, B.; Eicher, C.; Warmann, S.W.; Seitz, G.; Fuchs, J.; Armeanu-Ebinger, S. Inhibition of Bcl-2 and Bcl-x enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr. Blood Cancer 2010, 55, 1089-1095.
62. Armeanu-Ebinger, S.; Fuchs, J.; Wenz, J.; Seitz, G.; Ruck, P.; Warmann, S.W. Proteasome inhibition overcomes trail resistance in human hepatoblastoma cells. Front. Biosci. 2012, 4, 2194-2202.
63. Cotter, F.E.; Johnson, P.; Hall, P.; Pocock, C.; al Mahdi, N.; Cowell, J.K.; Morgan, G. Antisense oligonucleotides suppress B-cell lymphoma growth in a scid-hu mouse model. Oncogene 1994, 9, 3049-3055.
64. Chan, S.L.; Lee, M.C.; Tan, K.O.; Yang, L.K.; Lee, A.S.; Flotow, H.; Fu, N.Y.; Butler, M.S.; Soejarto, D.D.; Buss, A.D.; et al. Identification of chelerythrine as an inhibitor of bclxl function. J. Biol. Chem. 2003, 278, 20453-20456.
65. Zhai, D.; Jin, C.; Satterthwait, A.C.; Reed, J.C. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 2006, 13, 1419-1421.
66. Doi, K.; Li, R.; Sung, S.S.; Wu, H.; Liu, Y.; Manieri, W.; Krishnegowda, G.; Awwad, A.; Dewey, A.; Liu, X.; et al. Discovery of marinopyrrole a (maritoclax) as a selective MCL-1 antagonist that overcomes ABT-737 resistance by binding to and targeting MCL-1 for proteasomal degradation. J. Biol. Chem. 2012, 287, 10224-10235.
67. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681.
68. Muchmore, S.W.; Sattler, M.; Liang, H.; Meadows, R.P.; Harlan, J.E.; Yoon, H.S.; Nettesheim, D.; Chang, B.S.; Thompson, C.B.; Wong, S.L.; et al. X-ray and nmr structure of human Bcl-xl, an inhibitor of programmed cell death. Nature 1996, 381, 335-341.
69. Lock, R.; Carol, H.; Houghton, P.J.; Morton, C.L.; Kolb, E.A.; Gorlick, R.; Reynolds, C.P.; Maris, J.M.; Keir, S.T.; Wu, J.; et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50, 1181-1189.
70. Schelman, W.R.; Mohammed, T.A.; Traynor, A.M.; Kolesar, J.M.; Marnocha, R.M.; Eickhoff, J.; Keppen, M.; Alberti, D.B.; Wilding, G.; Takebe, N.; et al. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investig. New Drugs 2014, 32, 295-302.
71. Schimmer, A.D.; Raza, A.; Carter, T.H.; Claxton, D.; Erba, H.; de Angelo, D.J.; Tallman, M.S.; Goard, C.; Borthakur, G. A multicenter phase I/II study of obatoclax mesylate administered as a 3-or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS One 2014, 9, e108694.
72. Modugno, M.; Banfi, P.; Gasparri, F.; Borzilleri, R.; Carter, P.; Cornelius, L.; Gottardis, M.; Lee, V.; Mapelli, C.; Naglich, J.G.; et al. MCL-1 antagonism is a potential therapeutic strategy in a subset of solid cancers. Exp. Cell. Res. 2014, doi:10.1016/j.yexcr.2014.11.022.
73. Molica, S. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of the german CLL-11 trial. Expert Rev. Anticancer Ther. 2015, 15, 9-15.
74. Arellano, M.L.; Borthakur, G.; Berger, M.; Luer, J.; Raza, A. A phase ii, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin. Lymphoma Myeloma Leukemia 2014, 14, 534-539.
75. Arisan, E.D.; Kutuk, O.; Tezil, T.; Bodur, C.; Telci, D.; Basaga, H. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat. 2010, 119, 271-281.
76. Ashimori, N.; Zeitlin, B.D.; Zhang, Z.; Warner, K.; Turkienicz, I.M.; Spalding, A.C.; Teknos, T.N.; Wang, S.; Nor, J.E. Tw-37, a small-molecule inhibitor of Bcl-2, mediates s-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol. Cancer Ther. 2009, 8, 893-903.
77. Konopleva, M.; Watt, J.; Contractor, R.; Tsao, T.; Harris, D.; Estrov, Z.; Bornmann, W.; Kantarjian, H.; Viallet, J.; Samudio, I.; et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic Gx15-070 (obatoclax). Cancer Res. 2008, 68, 3413-3420.
78. Mason, K.D.; Khaw, S.L.; Rayeroux, K.C.; Chew, E.; Lee, E.F.; Fairlie, W.D.; Grigg, A.P.; Seymour, J.F.; Szer, J.; Huang, D.C.; et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009, 23, 2034-2041.
79. Mohammad, R.M.; Goustin, A.S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical studies of Tw-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin. Cancer Res. 2007, 13, 2226-2235.
80. Oliver, L.; Mahe, B.; Gree, R.; Vallette, F.M.; Juin, P. HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells. Leuk. Res. 2007, 31, 859-863.
81. Trudel, S.; Stewart, A.K.; Li, Z.; Shu, Y.; Liang, S.B.; Trieu, Y.; Reece, D.; Paterson, J.; Wang, D.; Wen, X.Y. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin. Cancer Res. 2007, 13, 621-629.
82. Champa, D.; Russo, M.A.; Liao, X.H.; Refetoff, S.; Ghossein, R.A.; di Cristofano, A. Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering BCL2A1 and MCL1 overexpression. Endocr. Relat. Cancer 2014, 21, 755-767.
83. Koehler, B.C.; Scherr, A.L.; Lorenz, S.; Elssner, C.; Kautz, N.; Welte, S.; Jaeger, D.; Urbanik, T.; Schulze-Bergkamen, H. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One 2014, 9, e106571.
84. Vogler, M.; Weber, K.; Dinsdale, D.; Schmitz, I.; Schulze-Osthoff, K.; Dyer, M.J.; Cohen, G.M. Different forms of cell death induced by putative Bcl2 inhibitors. Cell Death Differ. 2009, 16, 1030-1039.
85. Lieber, J.; Ellerkamp, V.; Wenz, J.; Kirchner, B.; Warmann, S.W.; Fuchs, J.; Armeanu-Ebinger, S. Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells. Pediatr. Surg. Int. 2011, 28, 149-159.
86. Lieber, J.; Dewerth, A.; Wenz, J.; Kirchner, B.; Eicher, C.; Warmann, S.W.; Fuchs, J.; Armeanu-Ebinger, S. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737. Oncol. Rep. 2013, 29, 646.
87. Lieber, J.; Eicher, C.; Wenz, J.; Kirchner, B.; Warmann, S.W.; Fuchs, J.; Armeanu-Ebinger, S. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer 2011, 11, 362.
88. Kim, H.; Tu, H.C.; Ren, D.; Takeuchi, O.; Jeffers, J.R.; Zambetti, G.P.; Hsieh, J.J.; Cheng, E.H. Stepwise activation of Bax and Bak by tBid, Bim, and puma initiates mitochondrial apoptosis. Mol. Cell 2009, 36, 487-499.
89. Skommer, J.; Brittain, T.; Raychaudhuri, S. Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. Apoptosis 2010, 15, 1223-1233.
90. Griffiths, G.J.; Dubrez, L.; Morgan, C.P.; Jones, N.A.; Whitehouse, J.; Corfe, B.M.; Dive, C.; Hickman, J.A. Cell damage-induced conformational changes of the pro-apoptotic protein bak in vivo precede the onset of apoptosis. J. Cell Biol. 1999, 144, 903-914.
91. Analysis, R.R.D.f.G.E. Available online: http://157.82.78.238/refexa/main_search.Jsp%5D (accessed on 10 January 2015).
92. E-MEXP-1851, D. Available online: http://www.Ebi.Ac.Uk/arrayexpress%5D (accessed on 15 August 2012).
93. Malogolowkin, M.H.; Katzenstein, H.M.; Krailo, M.; Chen, Z.; Quinn, J.J.; Reynolds, M.; Ortega, J.A. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J. Clin. Oncol. 2008, 26, 2379-2383.
94. Wang, J.L.; Liu, D.; Zhang, Z.J.; Shan, S.; Han, X.; Srinivasula, S.M.; Croce, C.M.; Alnemri, E.S.; Huang, Z. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 2000, 97, 7124-7129.
95. Jane, E.P.; Premkumar, D.R.; Morales, A.; Foster, K.A.; Pollack, I.F. Inhibition of phosphatidylinositol 3-kinase/Akt signaling by Nvp-Bkm120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells. J. Pharmacol. Exp. Ther. 2014, 350, 22-35.
96. Lickliter, J.D.; Wood, N.J.; Johnson, L.; McHugh, G.; Tan, J.; Wood, F.; Cox, J.; Wickham, N.W. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia 2003, 17, 2074-2080.
97. Manero, F.; Gautier, F.; Gallenne, T.; Cauquil, N.; Gree, D.; Cartron, P.F.; Geneste, O.; Gree, R.; Vallette, F.M.; Juin, P. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 2006, 66, 2757-2764.
98. Niizuma, H.; Nakamura, Y.; Ozaki, T.; Nakanishi, H.; Ohira, M.; Isogai, E.; Kageyama, H.; Imaizumi, M.; Nakagawara, A. Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma. Oncogene 2006, 25, 5046-5055.
99. Hermanson, D.; Addo, S.N.; Bajer, A.A.; Marchant, J.S.; Das, S.G.; Srinivasan, B.; Al-Mousa, F.; Michelangeli, F.; Thomas, D.D.; Lebien, T.W.; et al. Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. Mol. Pharmacol. 2009, 76, 667-678.
100. Pei, X.Y.; Dai, Y.; Grant, S. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol. Cancer Ther. 2004, 3, 1513-1524.
101. Doshi, J.M.; Tian, D.; Xing, C. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4hchromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis. Mol. Pharm. 2007, 4, 919-928.
102. Tian, D.; Das, S.G.; Doshi, J.M.; Peng, J.; Lin, J.; Xing, C. Sha 14-1, a stable and ros-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett. 2008, 259, 198-208.
103. Wang, G.; Nikolovska-Coleska, Z.; Yang, C.Y.; Wang, R.; Tang, G.; Guo, J.; Shangary, S.; Qiu, S.; Gao, W.; Yang, D.; et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem. 2006, 49, 6139-6142.
104. Forastiere, A.A. Chemotherapy in the treatment of locally advanced head and neck cancer. J. Surg. Oncol. 2008, 97, 701-707.
105. Lejeune, F.J.; Lienard, D.; Matter, M.; Ruegg, C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006, 6, 6.
106. Nakamoto, T.; Inagawa, H.; Takagi, K.; Soma, G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res. 2000, 20, 4087-4096.
107. Lieber, J.; Ellerkamp, V.; Vogt, F.; Wenz, J.; Warmann, S.W.; Fuchs, J.; Armeanu-Ebinger, S. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma. Exp. Cell Res. 2014, 322, 217-225.
108. Pathil, A.; Armeanu, S.; Venturelli, S.; Mascagni, P.; Weiss, T.S.; Gregor, M.; Lauer, U.M.; Bitzer, M. Hdac inhibitor treatment of hepatoma cells induces both trail-independent apoptosis and restoration of sensitivity to trail. Hepatology 2006, 43, 425-434.
109. Wajant, H. The fas signaling pathway: More than a paradigm. Science 2002, 296, 1635-1636.
110. Grutzmacher, C.; Park, S.; Elmergreen, T.L.; Tang, Y.; Scheef, E.A.; Sheibani, N.; Sorenson, C.M. Opposing effects of bim and Bcl-2 on lung endothelial cell migration. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299, L607-L620.
111. Sheibani, N.; Scheef, E.A.; Dimaio, T.A.; Wang, Y.; Kondo, S.; Sorenson, C.M. Bcl-2 expression modulates cell adhesion and migration promoting branching of ureteric bud cells. J. Cell. Physiol. 2007, 210, 616-625.
112. Koehler, B.C.; Scherr, A.L.; Lorenz, S.; Urbanik, T.; Kautz, N.; Elssner, C.; Welte, S.; Bermejo, J.L.; Jager, D.; Schulze-Bergkamen, H. Beyond cell death-Antiapoptotic Bcl-2 proteins regulate migration and invasion of colorectal cancer cells in vitro. PLoS One 2013, 8, e76446.
113. Vogt, F.; Lieber, J.; Dewerth, A.; Hoh, A.; Fuchs, J.; Armeanu-Ebinger, S. BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells. Exp. Cell Res. 2013, 319, 1443-1450.
114. Koch, A.; Waha, A.; Hartmann, W.; Hrychyk, A.; Schuller, U.; Wharton, K.A., Jr.; Fuchs, S.Y.; von Schweinitz, D.; Pietsch, T. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin. Cancer Res. 2005, 11, 4295-4304.
115. Von Schweinitz, D.; Kraus, J.A.; Albrecht, S.; Koch, A.; Fuchs, J.; Pietsch, T. Prognostic impact of molecular genetic alterations in hepatoblastoma. Med. Pediatr. Oncol. 2002, 38, 104-108.
116. Hwang, J.J.; Kuruvilla, J.; Mendelson, D.; Pishvaian, M.J.; Deeken, J.F.; Siu, L.L.; Berger, M.S.; Viallet, J.; Marshall, J.L. Phase i dose finding studies of obatoclax (Gx15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res. 2010, 16, 4038-4045.
117. Schimmer, A.D.; O'Brien, S.; Kantarjian, H.; Brandwein, J.; Cheson, B.D.; Minden, M.D.; Yee, K.; Ravandi, F.; Giles, F.; Schuh, A.; et al. A phase i study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14, 8295-8301.
118. Langer, C.J.; Albert, I.; Ross, H.J.; Kovacs, P.; Blakely, L.J.; Pajkos, G.; Somfay, A.; Zatloukal, P.; Kazarnowicz, A.; Moezi, M.M.; et al. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer 2014, 85, 420-428.
119. Souers, A.J.; Leverson, J.D.; Boghaert, E.R.; Ackler, S.L.; Catron, N.D.; Chen, J.; Dayton, B.D.; Ding, H.; Enschede, S.H.; Fairbrother, W.J.; et al. ABT-199, a potent and selective Bcl-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19, 202-208.
120. Kaefer, A.; Yang, J.; Noertersheuser, P.; Mensing, S.; Humerickhouse, R.; Awni, W.; Xiong, H. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother. Pharmacol. 2014, 74, 593-602.
121. Johnson-Farley, N.; Veliz, J.; Bhagavathi, S.; Bertino, J.R. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib, and JQ1 in "double hit" lymphoma cells. Leukemia Lymphoma 2014, 1, 1-12.
122. Peirs, S.; Matthijssens, F.; Goossens, S.; van de Walle, I.; Ruggero, K.; de Bock, C.E.; Degryse, S.; Cante-Barrett, K.; Briot, D.; Clappier, E.; et al. ABT-199 mediated inhibition of Bcl-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 2014, 124, 3738-3747.
123. Zeuner, A.; Francescangeli, F.; Contavalli, P.; Zapparelli, G.; Apuzzo, T.; Eramo, A.; Baiocchi, M.; de Angelis, M.L.; Biffoni, M.; Sette, G.; et al. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-xl inhibition in non-small cell lung cancer. Cell Death Differ. 2014, 21, 1877-1888.
124. Davids, M.S.; Letai, A. ABT-199: Taking dead aim at Bcl-2. Cancer Cell 2013, 23, 139-141.